TMO Stock: Price, Earnings History and SEC Filings
Thermo Fisher Scientific Inc. (TMO) last traded at $697.00, down 1.72% on the latest session and up 3.3% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $6.68 against an analyst estimate of $6.40, a beat of 4.4%.
$697.00 -1.72%
1 month+3.25%
52-week high$711.85
52-week low$435.27
Volume2.09M
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TMO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 21, 2026 | $6.68 | $6.40 | +4.37% |
| Jun 2026 | Jul 23, 2026 | $6.03 | $5.71 | +5.60% |
| Mar 2026 | Apr 23, 2026 | $5.44 | $5.20 | +4.62% |
| Dec 2025 | Jan 29, 2026 | $6.57 | $6.43 | +2.18% |
TMO beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for TMO
SEC filing data is not available right now. You can search for TMO on SEC EDGAR.
TMO news
- Thermo Fisher Scientific (TMO) Stock Fair Value Rises After Q3 Beat And Higher GuidanceOct 31, 2026 · finance.yahoo.com
- How Investors Are Reacting To Thermo Fisher Scientific Stock After Strong Q3 EarningsOct 31, 2026 · finance.yahoo.com
- Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGENOct 30, 2026 · finance.yahoo.com
- Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AIOct 30, 2026 · finance.yahoo.com
- Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and RocheOct 30, 2026 · finance.yahoo.com
- Clinical Genomics Sequencing, Biobank, and Database Services Global Market to 2035 | Capitalize on AI and Precision Medicine: Illumina, Thermo Fisher, BGI Genomics, Tempus AIOct 30, 2026 · finance.yahoo.com
- Global CRISPR Fluorescence Assays Market Report 2026 | Capitalize on 19.5% CAGR to 2030 with Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences Driving Multiplex DiagnosticsOct 30, 2026 · finance.yahoo.com
- Global Fetal Aneuploidy Confirmation Testing Market Report 2026 | Capitalize on 10.6% CAGR to $2.36 Billion by 2030 with Thermo Fisher, Labcorp, Quest Diagnostics and IlluminaOct 30, 2026 · finance.yahoo.com
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. (TMO) is a US-listed public company on NYSE.